Alpha 2.0
Login Register
» Authors » Wilson M Compton

Wilson M Compton

Explore the profile of Wilson M Compton including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 219
Citations 10938
Followers 0
Related Specialties
Psychiatry
General Medicine
Public Health
Top 10 Co-Authors
Beth Han
Christopher M Jones
Carlos Blanco
Nora D Volkow
Heather L Kimmel
Emily B Einstein
Nicolette Borek
Andrew Hyland
Cassandra A Stanton
Maansi Bansal-Travers
Published In
Drug Alcohol Depend
JAMA Netw Open
Am J Psychiatry
JAMA Psychiatry
JAMA
Affiliations
Soon will be listed here.
Recent Articles
1.
Correction to: Association of tobacco product use with chronic obstructive pulmonary disease (COPD) prevalence and incidence in waves 1 through 5 (2013-2019) of the population assessment of tobacco and health (PATH) study
Paulin L, Halenar M, Edwards K, Lauten K, Stanton C, Taylor K, et al.
Respir Res . 2025 Mar; 26(1):93. PMID: 40057741
No abstract available.
2.
Tobacco and E-Product Use by US Adults With Disabilities
Parks M, Marshall D, Kimmel H, Kingsbury J, Everard C, Aboaziza E, et al.
JAMA Netw Open . 2025 Feb; 8(2):e2460471. PMID: 39964679
Importance: Research on cumulative disabilities and tobacco use in the current tobacco landscape is lacking. Objective: To examine prevalence of tobacco use across cumulative disabilities within and across years among...
3.
Medically Recommended vs Nonmedical Cannabis Use Among US Adults
Han B, Compton W, Einstein E, Volkow N
JAMA Psychiatry . 2025 Jan; 82(3):319-321. PMID: 39841454
No abstract available.
4.
Prevalence of cannabis consumption methods among people with medically recommended and nonmedical cannabis use in the United States
Han B, Jones C, Volkow N, Einstein E, Weiss S, Blanco C, et al.
Addiction . 2025 Jan; PMID: 39838511
Aims: Some cannabis consumption methods (e.g. smoking, vaping, dabbing) are associated with more harms than others (e.g. sublingual, transdermal). We aimed to examine differences in prevalence of cannabis consumption methods...
5.
Research on Noncigarette Tobacco Products and Public Health
Compton W
JAMA Netw Open . 2025 Jan; 8(1):e2453969. PMID: 39804651
No abstract available.
6.
Reductions in Substance Use as Outcome Targets for Treatment Development
Compton W, Volkow N
Am J Psychiatry . 2024 Nov; 181(11):947-948. PMID: 39482950
No abstract available.
7.
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use
Compton W, Einstein E, Han B
Am J Psychiatry . 2024 Nov; 181(11):1018-1021. PMID: 39482948
No abstract available.
8.
Opportunities for Innovation in Smoking Cessation Therapies: A Perspective From the National Institutes of Health and U.S. Food and Drug Administration
Warraich H, King B, Compton W, Herrmann E, Hai M, Califf R, et al.
Ann Intern Med . 2024 Oct; 178(1):122-125. PMID: 39401434
No abstract available.
9.
Household Compositions and Substance Use among Young Adults in the U.S
Han B, Tomoyasu N, Einstein E, Jones C, Compton W
Int J Environ Res Public Health . 2024 Aug; 21(8). PMID: 39200676
Background: Adults aged 21-29 have the highest past-month prevalence of tobacco, alcohol, and illicit drug use in the U.S. Currently, young adults often delay traditional adulthood milestones (e.g., marriage and...
10.
Prescription Opioid Use Disorder Among Adults Reporting Prescription Opioid Use With or Without Misuse in the United States
Han B, Jones C, Einstein E, Dowell D, Compton W
J Clin Psychiatry . 2024 Jul; 85(3). PMID: 39028542
We examined prescription related opioid use disorder (POUD) prevalence, individual symptoms, severity, characteristics, and treatment by prescription opioid misuse status among adults with prescription opioid use. Cross-sectional study using nationally...